ClinicalTrials.gg
RecruitingNCT06933381Updated Oct 13, 2026

Vapocoolant Spray to Reduce Pain With Nexplanon Insertion

An interventional study of Vapocoolant spray and Placebo in Reducing Pain With Nexplanon Implant Insertion, sponsored by Queen's Medical Center. Recruiting at 3 sites in United States. Open to female participants aged 14 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Queen's Medical Center · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.
Updated Oct 13, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
14 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,886 studies in Pain with a site in United States — 315 open to participants now, 393 under way, 24 of them phase 3. Pain · United States.

Planned enrollment
1,233rd of 2,564
70 · median 66
Started
2025
with 128 others
No phase
1,244 of 2,886
183 open now
Primary completion
2027-03
later than 161 of 392 live
Registered
2,707th of 2,886
by date

Among the 2,886 studies in Pain with a site in United States, this one is the 1,233rd largest by planned enrollment of the 2,564 interventional ones that give a count, is one of 129 that started in 2025, is one of 1,244 with no phase, reaches primary completion later than 161 of the 392 other live ones, and was the 2,707th registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

315 of the 2,886 studies in Pain with a site in United States are open now. Recruiting first, the newest first:

310 more — sign in →

All 315 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.

This study: 14 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,886 studies in Pain with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess if Pain Ease vapocoolant spray decreases pain associated with lidocaine injection during Nexplanon insertion procedures.

Read the detailed description

This study will be for patients in the office having a Nexplanon (etonogestrel implant) insertion. The doctor in clinic will evaluate if a patient meets eligibility criteria for this study. If the patient meets eligibility criteria, the doctor will inform the patient of the study and the potential risks. If patients elect to participate, a research coordinator will obtain written informed consent. The patient will be randomized (patient is blinded) to receive either Pain Ease vapocoolant spray or placebo (normal saline) spray. They will receive the spray just before lidocaine injection during the Nexplanon insertion procedure. The purpose of the study is to see if Pain Ease vapocoolant spray reduces patient pain during lidocaine injection for Nexplanon insertion.

03

Conditions studied

  • Reducing Pain With Nexplanon Implant Insertion

Browse trials for

Keywords

  • Vapocoolant spray
  • Pain with Nexplanon insertion
  • Contraceptive implant insertion
  • Vapocoolant
04

Who can participate

Ages eligible
14 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 14 years or older
  • Undergoing an etonogestrel implant insertion in the arm in POB1 Suite 1004 or POB2 Suite 402
  • English speaking
  • Able and willing to sign the form and agree to terms of the study

Exclusion criteria

Exclusion Criteria:

  • Required or requested narcotics, anxiolytics, IV sedation, or general anesthesia for the procedure
  • Known previous exposure to vapocoolant spray
  • Nexplanon removal and reinsertion same day during visit in the same arm
  • to vapocoolant spray components (ethyl chloride and 1,1,1,3,3-pentafluoropropane/1,1,1,2-tetrafluroethane)
  • Unable to provide written, in English
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Vapocoolant Spray

    This is the study arm. Participants in this arm of the study will receive Pain Ease vapocoolant spray during their Nexplanon implant insertion in the arm. They will receive the spray on their arm right before lidocaine injection is administered for Nexplanon insertion procedure. Pain Ease vapocoolant spray is FDA approved for use on skin prior to common needle-stick procedures like intravenous (IV) starts and vaccines. The investigators will use the spray in a similar fashion, to help with the pain of lidocaine injection during Nexplanon insertion procedures. Physicians will do the Nexplanon procedure before any other procedures if patient has multiple procedures scheduled the same day.

    Device: Vapocoolant spray

  • Placebo comparator
    Nature's Tears

    This is the placebo. This group will receive Nature's Tears, which is a saline spray that does not offer analgesic effects.

    Other: Placebo

Interventions

  • DeviceVapocoolant spray

    Pain Ease will be used per manufacturer instruction, applying the spray for 5 seconds or until the skin turns white, whichever occurs first.

    Also known as: Pain Ease

  • OtherPlacebo

    Nature's Tears will be applied to the arm as a placebo spray

    Also known as: Nature's Tears

06

What researchers measure

Primary outcomes

  1. Pain with lidocaine injection

    The investigators will ask patients to rate their pain with lidocaine injection that precedes Nexplanon insertion using a visual analog scale (VAS). The visual analog scale is a 100 mm line, with values 0 to 100. 0 is marked as no pain and 100 is marked as worst pain.

    Time frame: Immediately after lidocaine injection

Secondary outcomes

  1. Patient satisfaction

    Patients will be asked about their satisfaction with pain control for the procedure and satisfaction for the procedure overall using a survey with 5 options, including very unsatisfied, unsatisfied, neutral, satisfied, and very satisfied.

    Time frame: Immediately after procedure

  2. Pain Reduction with Remainder of Procedure

    Participants will be asked to rate their pain using a visual analog scale (VAS) in regard to pain when the implant was inserted. The visual analog scale is a 100 mm line, with values 0 to 100. 0 is marked as no pain and 100 is marked as worst pain.They will also be asked about their pain for the procedure overall using a Likert scale from 0 (no pain) to 10 (severe pain).

    Time frame: Immediately after the procedure

07

Study locations

2 of 3 sites recruiting
  • Queens Medical Center POB 2 Suite 402
    Honolulu, Hawaii 96813, United States
    Recruiting
    • Sarah Murayama, MD · Contactsmura@hawaii.edu · 808-783-0298
    • Mary Tschann, PhD · Contact808-375-3785
    • Sarah Murayama, MD · Principal investigator
    • Bliss Kaneshiro, MD MPH · Principal investigator
  • Queens Medical Center POB1 Clinic 1004
    Honolulu, Hawaii 96813, United States
    Recruiting
    • Sarah Murayama, MD · Contactsmura@hawaii.edu · 808-783-0298
    • Mary Tschann, PhD · Contactmtschann@hawaii.edu · 808-375-3785
    • Sarah Murayama, MD · Principal investigator
    • Bliss Kaneshiro, MD MPH · Principal investigator
  • Women's Center Queen's North Hawai'i Community Hospital Suite #124 and #120
    Waimea, Hawaii 96743, United States
    Not yet recruiting
    • Bliss Kaneshiro, MD, MPH · Contactblissk@hawaii.edu · 808-372-7560
    • Bliss Kaneshiro, MD, MPH · Principal investigator
08

References and documents

Publications

  • Todd KH, Funk KG, Funk JP, Bonacci R. Clinical significance of reported changes in pain severity. Ann Emerg Med. 1996 Apr;27(4):485-9. doi: 10.1016/s0196-0644(96)70238-x. PubMed 8604867 ↗
  • Mace SE. Prospective, randomized, double-blind controlled trial comparing vapocoolant spray vs placebo spray in adults undergoing venipuncture. Am J Emerg Med. 2016 May;34(5):798-804. doi: 10.1016/j.ajem.2016.01.002. Epub 2016 Jan 7. PubMed 26979261 ↗
  • Unal N, Tosun B, Aslan O, Tunay S. Effects of Vapocoolant Spray Prior to SC LMWH Injection: An Experimental Study. Clin Nurs Res. 2021 Feb;30(2):127-134. doi: 10.1177/1054773818825486. Epub 2019 Jan 30. PubMed 30698458 ↗
  • Zhu Y, Peng X, Wang S, Chen W, Liu C, Guo B, Zhao L, Gao Y, Wang K, Lou F. Vapocoolant spray versus placebo spray/no treatment for reducing pain from intravenous cannulation: A meta-analysis of randomized controlled trials. Am J Emerg Med. 2018 Nov;36(11):2085-2092. doi: 10.1016/j.ajem.2018.03.068. Epub 2018 Mar 27. PubMed 30253890 ↗
  • Collado-Mesa F, Net JM, Arheart K, Klevos GA, Yepes MM. Application of a topical vapocoolant spray decreases pain at the site of initial intradermal anaesthetic injection during ultrasound-guided breast needle biopsy. Clin Radiol. 2015 Sep;70(9):938-42. doi: 10.1016/j.crad.2015.04.013. Epub 2015 Jul 7. PubMed 26162573 ↗
  • Wilson GA, Jeter JW, Dabbs WS, Stevens AB, Heidel RE, Chamberlin SM. Comparison of traditional anesthesia method and jet injector anesthesia method (MadaJet XL(R)) for Nexplanon(R) insertion and removal. Contracept Reprod Med. 2020 Feb 24;5:1. doi: 10.1186/s40834-020-00104-x. eCollection 2020. PubMed 32123573 ↗
  • Bentsianov SD, Brandi K, Chen P, Shimoni N. A Pilot Study to Understand the Adolescent Pain Experience During Contraceptive Implant Insertion. J Pediatr Adolesc Gynecol. 2021 Aug;34(4):522-524. doi: 10.1016/j.jpag.2021.01.013. Epub 2021 Jan 27. PubMed 33515699 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Mar 2027, 20 months after the start.

Of 3,749 non-industry interventional studies with no phase under Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 23. This study's planned 20 months is above that.

Counting every sponsor, half of 3,848 studies reached it within 10 months; a quarter within 4 and three quarters within 23.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Apr 2026 → Mar 2027 and completion May 2026 → Jul 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2025
First posted
Apr 18, 2025
StartActual
Jun 16, 2025
Primary completionEst.
Mar 1, 2027was Apr 2026
CompletionEst.
Jul 1, 2027was May 2026
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Apr 1, 2026→Mar 1, 2027
Oct 13, 2026
Study completion
May 1, 2026→Jul 1, 2027
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Primary completion Apr 1, 2026→Mar 1, 2027
    Study completion May 1, 2026→Jul 1, 2027

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06933381
Lead sponsor
Queen's Medical Center
Collaborators
Lakshmi Devi and Devraj Sharma Endowment
Responsible party
Sponsor
First posted
Apr 18, 2025
Start date
Jun 16, 2025
Primary completion
Mar 1, 2027 (estimated)
Completion
Jul 1, 2027 (estimated)
Last update
Oct 13, 2026

Study contacts

Sarah Murayama, MD
Contact
smura@hawaii.edu
808-783-0298
Mary Tschann, PhD
Contact
mtschann@hawaii.edu
808-375-3785

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion